The first European interdisciplinary ewing sarcoma research summit

Area of Science:

• Pediatric oncology
• Sarcoma research
• Cancer biology

Background:

• Current chemotherapy for sarcomas, particularly metastatic Ewing sarcoma (ES), has limitations, with survival rates below 20% for ES.
• Despite advances in understanding ES biology, clinical application of research findings is hindered by fragmented efforts and lack of a collaborative forum.
• The European Network for Cancer Research in Children and Adolescents (ENCCA) aims to bridge this gap.

Purpose of the Study:

• To establish biology-based prioritization for innovative targets, drugs, and prognostic markers in pediatric cancers.
• To address the urgent need for novel therapeutics in sarcomas, especially metastatic Ewing sarcoma.
• To foster collaboration and knowledge exchange among European and North American experts in ES research.

Main Methods:

• Convening 30 European expert scientists and 5 North American opinion leaders in December 2011.
• Facilitating discussions on the state-of-the-art in Ewing sarcoma research and recent bench results.
• Proposing biological studies and novel therapeutics for upcoming European clinical trials (EWING2008 and EWING2012).

Main Results:

• A collaborative platform was established to address the fragmentation in Ewing sarcoma research.
• Discussions focused on translating laboratory discoveries into clinical practice for pediatric sarcomas.
• Strategies for prioritizing and validating new therapeutic approaches were initiated.

Conclusions:

• ENCCA serves as a crucial interaction platform for pediatric cancer research and care stakeholders.
• The initiative aims to accelerate the clinical translation of promising Ewing sarcoma research.
• Enhanced collaboration is essential for developing improved treatment options for children with sarcomas.